Combining rimonabant and fentanyl in a single entity: Preparation and pharmacological results

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 263-277

  Fernández Fernández, Cristina ^a   Callado, Luis F ^b   Girón, Rocío ^c   Sánchez, Eva ^c   Erdozain, Amaia M ^b   López Moreno, José Antonio ^d   Morales, Paula ^a   de Fonseca, Fernando Rodríguez ^e   Fernández Ruiz, Javier ^d   Goya, Pilar ^a   Javier Meana, J ^b   Isabel Martin M ^c   Jagerovic, Nadine ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c UNIVERSIDAD REY JUAN CARLOS   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e Hospital University Carlos Haya de Málaga   (Spain)

Author keywords

Behavioral assays; Cannabinoid; Fentanyl; Opioid; Rimonabant

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (12 (N (1 PHENETHYLPIPERIDIN 4 YL)PROPIONAMIDO)DODECYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (3 (N (1 PHENETHYLPIPERIDIN 4 YL)PROPIONAMIDO)PHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (3 (N (1 PHENETHYLPIPERIDIN 4YL)PROPIONAMIDO)BENZYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (3 (N (1 PHENETHYLPIPERIDIN 4YL)PROPIONAMIDO)PROPYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (4 (N (1 PHENETHYLPIPERIDIN 4 YL)PROPIONAMIDO)BUTYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (4 [(4 N (1 PHENETHYLPIPERIDIN 4YL)PROPIONAMIDO)CYCLOHEXY]METHYL)CYCLO HEXYL 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (5 (N (1 PHENETHYLPIPERIDIN 4 YL)PROPIONAMIDO)PENTYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (6 (N (1 PHENETHYLPIPERIDIN 4 YL)PROPIONAMIDO)HEXYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (7 (N (1 PHENETHYLPIPERIDIN 4 YL)PROPIONAMIDO)HEPTYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (8 (N (1 PHENETHYLPIPERIDIN 4 YL)PROPIONAMIDO)OCTYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (9 (N (1 PHENETHYLPIPERIDIN 4 YL)PROPIONAMIDO)NONYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; FENTANYL; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; OPIATE; RIMONABANT; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALCOHOL CONSUMPTION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BEHAVIOR CHANGE; BINDING AFFINITY; CATALEPSY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; EMBRYO; FRONTAL CORTEX; HOT PLATE TEST; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIPOPHILICITY; LOCOMOTION; MALE; MOUSE; NOCICEPTION; NONHUMAN; RAT; RECEPTOR BINDING ASSAY; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; METABOLISM;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FENTANYL; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; MICE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84894766267     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S55045     Document Type: Article

References (36)

1. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci. 1999;20(7): 287-294.
2. Vigano D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav. 2005;81(2):360-368.
3. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90(6):844-851.
4. Maldonado R, Berrendero F. Endogenous cannabinoid and opioid systems and their role in nicotine addiction. Curr Drug Targets. 2010;11(4): 440-449.
5. Christie MJ. Opioid and cannabinoid receptors: friends with benefits or just close friends? Br J Pharmacol. 2006;148(4):385-386.
6. Trang T, Sutak M, Jhamandas K. Involvement of cannabinoid (CB1)-receptors in the development and maintenance of opioid tolerance. Neuroscience. 2007;146(3):1275-1288.
7. Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal. Neuroscience. 2013;248:637-654.
8. Morphy R, Rankovic Z. Designing multiple ligands-medicinal chemistry strategies and challenges. Curr Pharm Des. 2009;15(6):587-600.
9. Shonberg J, Scammells PJ, Capuano B. Design strategies for bivalent ligands targeting GPCRs. Chem Med Chem. 2011;6(6):963-974.
10. Davis MP. Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother. 2011;11(8):1197-1216.
11. Jagerovic N, Fernandez-Fernandez C, Goya P. CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr Top Med Chem. 2008;8(3):205-230.
12. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther. 2011;36(1):10-18.
13. Montero A, Goya P, Jagerovic N, et al. Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for mu opioid and I2-imidazoline receptors: synthesis and pharmacological screening. Bioorg Med Chem. 2002;10(4):1009-1018.
14. Dardonville C, Fernandez-Fernandez C, Gibbons SL, et al. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I-2-imidazoline binding sites. Bioorg Med Chem. 2006;14(19):6570-6580.
15. Thomas BF, Francisco MEY, Seltzman HH, et al. Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-py razole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorg Med Chem. 2005;13(18): 5463-5474.
16. Fernandez-Fernandez C, Decara J, Bermúdez-Silva FJ, et al. Description of a bivalent cannabinoid ligand with hypophagic properties. Arch Pharm. 2013;346(3):171-179.
17. Sasmal PK, Reddy DS, Talwar R, et al. Novel pyrazole-3-carboxamide derivatives as cannabinoid-1 (CB1) antagonists: journey from non-polar to polar amides. Bioorg Med Chem Lett. 2011;21(1):562-568.
18. Dardonville C, Jagerovic N, Callado LF, Meana JJ. Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I2-imidazoline binding sites. Bioorg Med Chem Lett. 2004;14(2):491-493.
19. Krishnamurthy M, Li W, Moore BM 2nd. Synthesis, biological evaluation, and structural studies on N1 and C5 substituted cycloalkyl analogues of the pyrazole class of CB1 and CB2 ligands. Bioorg Med Chem. 2004;12(2):393-404.
20. De Jesus ML, Salles J, Meana JJ, Callado LF. Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates. Neuroscience. 2006;140(2):635-643.
21. Cumella J, Hernandez-Folgado L, Giron R, et al. Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties. ChemMedChem. 2012;7(3):452-463.
22. 35S]GTPgammaS binding to cortical membranes from postmortem human brain. Eur J Pharmacol. 2000;390(1-2):25-36.
23. Pertwee RG. The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmacol. 1972;46(4): 753-763.
24. Serra S, Carai MA, Brunetti G, et al. The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats. Eur J Pharmacol. 2001;430(2-3):369-371.
25. Erdozain AM, Diez-Alarcia R, Meana JJ, Callado LF. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain. Biochem Pharmacol. 2012;83(2):260-268.
26. Rowland NE, Mukherjee M, Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology. 2001;159(1):111-116.
27. Robledo P, Berrendero F, Ozaita A, Maldonado R. Advances in the field of cannabinoid-opioid cross-talk. Addict Biol. 2008;13(2):213-224.
28. Tallett AJ, Blundell JE, Rodgers RJ. Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats. Pharmacol Biochem Behav. 2009;91(3): 358-366.
29. Wright FL, Rodgers RJ. Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology. 2013;226(2):415-431.
30. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol. 1992;105(4):980-984.
31. Heyser CJ, Moc K, Koob GF. Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology. 2003;28(8):1463-1471.
32. Lopez-Moreno JA, Gonzalez-Cuevas G, Rodriguez de Fonseca F, Navarro M. Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation. J Neurosci. 2004;24(38):8245-8252.
33. Bowen JP, Guner OF. A perspective on quantum mechanics calculations in ADMET predictions. Curr Top Med Chem. 2013;13(11): 1257-1272.
34. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
35. Jorgensen WL, Duffy EM. Prediction of drug solubility from structure. Adv Drug Deliv Rev. 2002;54(3):355-366.
36. Le Naour M, Akgun E, Yekkirala A, et al. Bivalent ligands that target mu opioid (MOP) and cannabinoid1 (CB) receptors are potent analgesics devoid of tolerance. J Med Chem. 2013;56(13):5505-5513.